ICER thresholds

Market Access

The ICER threshold increase is expected to allow an additional three to five medicines or indications each year to be recommended for NHS use.

News

Astellas takes an option on a cancer immunotherapy developed by Audax for up to $1.34bn, with Gilead and Teva also adding to their pipelines.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.